|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although met with conflicting data, the following genes may be involved with TD development: the cytochrome P450 gene CYP2D6, involved with metabolism of most antipsychotics, Dopamine D2 and D3 receptor genes, serotonin 2A and 2C receptor genes, vesicular monoamine transporter 2 (VMAT 2) gene, involved with intracellular neurotransmitter packaging, and the manganese superoxide dismutase (MnSOD) gene, an antioxidant enzyme.
|
30522959 |
2019 |
|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ala-9Val polymorphism, a functional polymorphism of MnSOD gene, has been reported to be related to the risk of schizophrenia and TD.
|
26356721 |
2015 |
|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While the MnSOD gene Ala-9Val polymorphism did not play a major role in the susceptibility to TD in schizophrenic patients, it might be associated with negative symptoms of schizophrenia.
|
20346996 |
2010 |
|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neither the NQO1 Pro187Ser nor the SOD2 Ala9Val appear to play a major role in TD risk, although additional polymorphisms should be tested before the role of NQO1 and SOD2 in TD can be completely excluded.
|
19778569 |
2010 |
|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The combined genotypes of T/T in NQO1 Pro187Ser and Val/Val in MnSOD Ala-9Val polymorphisms were found to be independently associated with a significantly higher risk of TD.
|
18977034 |
2008 |
|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Search for these determinants has led to a few consensus associations of CYP2D6 *10, CYP1A2*1F, DRD2 Taq1A (rs1800497), DRD3 rs6280" genes_norm="1814">Ser9Gly (rs6280) and MnSOD Ala9Val (rs4880) variants with TD.
|
18781856 |
2008 |
|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evidence from pooled data for genetic association with tardive dyskinesia (TD) showed (1) in COMT(val158met), using Val-Val homozygotes as reference category, a protective effect for Val-Met heterozygotes (OR=0.63, 95% CI: 0.46-0.86, P=0.004) and Met carriers (OR=0.66, 95% CI: 0.49-0.88, P=0.005); (2) in Taq1A in DRD2, using the A1 variant as reference category, a risk-increasing effect for the A2 variant (OR=1.30, 95% CI: 1.03-1.65, P=0.026), and A2-A2 homozygotes using A1-A1 as reference category (OR=1.80, 95% CI: 1.03-3.15, P=0.037); (3) in MnSOD Ala-9Val, using Ala-Ala homozygotes as reference category, a protective effect for Ala-Val (OR=0.37, 95% CI: 0.17-0.79, P=0.009) and for Val carriers (OR=0.49, 95% CI: 0.24-1.00, P=0.047).
|
18180754 |
2008 |
|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study investigated the association of a MnSOD gene (MnSOD) polymorphism (Ala-9Val) with schizophrenia as well as its involvement in TD.
|
17582511 |
2007 |
|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the influence of a functional polymorphism of the dopamine D3 receptor (DRD3), and assess its interaction with a Mn superoxide dismutase (MnSOD) polymorphism, in contributing to tardive dyskinesia in a chronic inpatient population with schizophrenia.
|
12960753 |
2003 |
|
Tardive Dyskinesia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conjunction with previous findings of increased free radicals and decreased SOD activities in TD subjects, these results suggest that the -9Ala (high activity) MnSOD allele may play a role in protecting against susceptibility to TD in schizophrenics.
|
10882843 |
2000 |